| Schizophrenia
Invega Sustenna vs Latuda
Side-by-side clinical, coverage, and cost comparison for schizophrenia.Deep comparison between: Invega Sustenna vs Latuda with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLatuda has a higher rate of injection site reactions vs Invega Sustenna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Latuda but not Invega Sustenna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Invega Sustenna
Latuda
At A Glance
IM injection
Every 4 weeks
D2/5HT2A antagonist
Oral
Once daily
Atypical antipsychotic
Indications
- Schizophrenia
- Schizoaffective Disorder
- Schizophrenia
- Depression, Bipolar
Dosing
Schizophrenia Initiation: 234 mg deltoid on Day 1, 156 mg deltoid on Day 8; recommended monthly maintenance 117 mg (range 39-234 mg) in deltoid or gluteal muscle; maximum monthly dose 234 mg.
Schizoaffective Disorder Initiation: 234 mg deltoid on Day 1, 156 mg deltoid on Day 8; monthly maintenance 78-234 mg adjusted for tolerability and/or efficacy in deltoid or gluteal muscle; maximum monthly dose 234 mg.
Mild renal impairment (creatinine clearance >=50 mL/min) Initiation: 156 mg deltoid on Day 1, 117 mg deltoid on Day 8; monthly maintenance 39-156 mg; maximum monthly dose 156 mg.
Schizophrenia Adults: 40 mg once daily (range 40-160 mg/day); adolescents 13-17 years: 40 mg once daily (range 40-80 mg/day); take with food (at least 350 calories).
Depression, Bipolar Adults: 20 mg once daily as monotherapy or adjunctive therapy with lithium or valproate (range 20-120 mg/day); pediatric patients 10-17 years: 20 mg once daily as monotherapy (range 20-80 mg/day); take with food (at least 350 calories).
Contraindications
- Known hypersensitivity to paliperidone, risperidone, or any excipient in the INVEGA SUSTENNA formulation
- Known hypersensitivity to lurasidone HCl or any components in the formulation
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil)
- Concomitant use with strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine)
Adverse Reactions
Most common (>=5%) Injection site reactions, somnolence/sedation, dizziness, akathisia, extrapyramidal disorder
Serious Increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse reactions, neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia, metabolic changes, orthostatic hypotension and syncope, leukopenia/neutropenia/agranulocytosis, hyperprolactinemia, seizures
Postmarketing Angioedema, anaphylactic reaction, catatonia, ileus, somnambulism, swollen tongue, thrombotic thrombocytopenic purpura, urinary incontinence, urinary retention
Most common (>=5%) Somnolence, akathisia, extrapyramidal symptoms, nausea, vomiting, diarrhea, anxiety
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, cerebrovascular adverse reactions, hyperprolactinemia, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension and syncope, seizures, body temperature dysregulation
Postmarketing Urticaria, throat swelling, tongue swelling, dyspnea, rash, hyponatremia
Pharmacology
Paliperidone palmitate is hydrolyzed to paliperidone, the major active metabolite of risperidone; its therapeutic effect in schizophrenia may be mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism, with additional antagonist activity at histamine H1 and alpha-1/alpha-2 adrenergic receptors.
Lurasidone is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors and as a partial agonist at 5-HT1A receptors, with little affinity for histamine H1 or muscarinic M1 receptors; its efficacy in schizophrenia and bipolar depression may be mediated through combined D2 and 5-HT2A receptor antagonism.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Invega Sustenna
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (4/12) · Qty limit (11/12)
Latuda
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
UnitedHealthcare
Invega Sustenna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Latuda
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Invega Sustenna
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Latuda
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Cancer-Related Behavioral Health
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Invega SustennaView full Invega Sustenna profile
LatudaView full Latuda profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.